Amgen Golden Tickets provide startup companies with free lab space to further advance innovative science and technology

AmgenAmgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics and PanTher Therapeutics have each won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge, Mass. facility on Dec. 11, 2018. Six finalists pitched their business plans to attendees where the audience members' votes served as input for the Amgen internal committee's decision.

As a LabCentral platinum sponsor, Amgen nominates two early-stage companies annually to take up residence in LabCentral's Kendall Square facilities in Cambridge. The Golden Ticket represents one year of free bench space for one scientist, including benefit of LabCentral's shared infrastructure and services (such as conference rooms, permits, shared equipment and facilities, participation in LabCentral training modules and seminars). Amgen scientists also provide on-going mentoring throughout the year. LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life sciences and biotech startups.

"Amgen enjoys hosting the Quick Pitch event where, for the second year, we team up with our industry colleagues to showcase the brightest and most promising innovations happening here in Cambridge," said John Dunlop, Ph.D., vice president of Neuroscience at Amgen. "Our goal is to identify, empower and enable the best startup companies to advance their innovative science and technologies. Awarding the LabCentral Golden Tickets to Kernal Biologics and PanTher Therapeutics fulfills our mission to serve patients. We look forward to learning and mentoring to bring forth the best in both companies."

"Receiving this Golden Ticket award for a second time from Amgen is a great honor and an affirmation of Kernal's disruptive mRNA 2.0 technology and unique approach in immuno-oncology," said Yusuf Erkul, M.D., president and co-founder of Kernal Biologics. "We look forward to bringing onco-selective mRNA immunotherapy to cancer patients."

"PanTher's lead program in pancreatic cancer is well advanced and entering the FDA and clinical trial stage, and we are pursuing a second-generation program," said Laura Indolfi, chief executive officer and co-founder of PanTher Therapeutics. "Continuing this work at LabCentral will enable PanTher to accelerate development but can also be instrumental in defining the path we want to pursue by interacting and receiving mentoring from Amgen scientists."

Kernal Biologics Inc. develops therapeutic messenger RNAs via deep learning for immuno-oncology applications. Kernal's unique methods of sequence engineering and smart design are intended to develop a technology platform that will dramatically improve the efficacy of existing mRNA technologies.

PanTher Therapeutics develops a novel delivery method for the treatment of inoperable locally advanced solid tumors. Its delivery method is designed to target just the tumor, which has the potential to enhance therapeutic response and minimize side effects. The company's first indication will be for pancreatic cancer.

Amgen has sponsored the LabCentral Golden Ticket program since 2014, which was launched to assist high-potential life sciences and biotech startups in their efforts to continue further research in advancing unique approaches to treatments for serious conditions. Amgen has awarded LabCentral Golden Tickets to seven innovative startups: Novopyxis, Cocoon Biotech, Platelet Biogenesis, Holobiome, Torus Therapeutics, QurAlis and Kernal Biologics.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

About LabCentral

LabCentral is the first-of-its-kind shared laboratory workspace in the heart of the Kendall Square, Cambridge, biotech innovation hub, designed as a launchpad for high-potential life-sciences and biotech startups. It offers everything young companies need to begin lab operations immediately upon move-in and propel their science forward faster and more cost-efficiently (10 to 20x less than going it alone!) This includes: beautifully designed, fully permitted lab and office space, first-class facility and administrative support, skilled lab personnel, peer learning and networking opportunities, an expert speaker series - as well as critical access to potential funders and industry partners. A private, nonprofit institution, the first site opened in 2013, with support from real-estate partner, MIT. Founding sponsors include Johnson & Johnson Innovation, the Massachusetts Life Sciences Center, Roche, and Triumvirate Environmental. To accommodate demand for growing startups, LabCentral 610 opened in late 2017, with support from Pfizer. LabCentral now has capacity to serve ~450 scientists and entrepreneurs in about 70 companies across its two-building campus. In 2017, it also added the LabCentral Learning Lab for STEM programming to help inspire the next generation of science entrepreneurs.

Most Popular Now

Novartis announces plan to initiate clinical trial…

Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the effic...

Gilead announces results from Phase 3 trial of inv…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigation...

AstraZeneca and Oxford University announce landmar…

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine a...

Sanofi and Regeneron provide update on U.S. Phase …

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzar...

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

Loss of smell associated with milder clinical cour…

Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published ...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...